Table 1.
Demographic and general clinical data of patients with symptomatic ATTRv Glu89Gln amyloidosis at enrollment in THAOS
| Overall (n = 91) |
Bulgaria (n = 53) |
Italy (n = 29) |
Other countries (n = 9) |
|
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 46 (50.5) | 28 (52.8) | 14 (48.3) | 4 (44.4) |
| Female | 45 (49.5) | 25 (47.2) | 15 (51.7) | 5 (55.6) |
| Race, Caucasian, % | 100 | 100 | 100 | 100 |
| Age at entry into THAOS, years, mean (SD) | 56.12 (8.23) | 57.11 (8.20) | 54.82 (8.63) | 54.41 (6.88) |
| Duration of ATTRv amyloidosis symptoms, years, mean (SD) | 7.30 (8.02) | 8.56 (9.55) | 5.04 (4.08) | 7.17 (6.36) |
| Karnofsky score, %, mean (SD) | 79.31 (15.91) | 83.02 (12.18) | 74.44 (20.25) | 70.00 (15.28) |
| mBMI, mean (SD) | 995.67 (261.43) | 988.51 (236.97) | 1061.51 (365.22) | 912.07 (238.11) |
ATTRv amyloidosis hereditary transthyretin amyloidosis, ATTRv Glu89Gln amyloidosis ATTRv amyloidosis associated with the Glu89Gln variant, mBMI modified body mass index, SD standard deviation, THAOS Transthyretin Amyloidosis Outcomes Survey (data cutoff, January 6, 2020)